When would you escalate moderate efficacy therapy for MS in a clinically stable patient with a single new clinically silent MRI lesion?

Sure.

What is 'moderate efficacy therapy'? How is that defined? And who defines that? Refs?

Secondly, a new lesion implies BBB breakdown (supposedly, if it is a T1 gad-enhancing lesion) and so, I would change therapy. My slant is always to use the best data available, so I would use the most efficac...